Alle Fälle anzeigen
ORD 22245/2025
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieVerfahrensführungsanordnungen
- Parteien
- Kläger
- Sanofi SA
- Sanofi Winthrop Industrie
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Vertreter: Frédéric Chevallier (McDermott Will & Schulte)Beklagte- Accord Healthcare S.L.U.
- Accord Healthcare GmbH
- Accord Healthcare B.V.
- Accord Healthcare Italia Srl
- Accord Healthcare AB
- STADAPHARM GmbH
- STADA Arzneimittel AG
- STADA Nordic ApS
- Reddy Pharma SAS
- betapharm Arzneimittel GmbH
- Dr Reddy's Srl
- Zentiva France
- Zentiva Pharma GmbH
- Zentiva, k.s.
Vertreter: Jules Fabre (Taylor Wessing); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing) - Division
- Munich LD
- Richter
- Matthias Zigann · Presiding judge and judge-rapporteur
- Technology
- Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 17. Juli 2025
Entscheidungen
- 2025-07-17Generic Order
The Munich Local Division issued a scheduling order following the interim conference in the Sanofi v. Accord/STADA/Reddy/Zentiva infringement actions, setting out next procedural steps pending the written reasoning from the EPO Board of Appeal decision on the relevant patent.
Rechtsfragen:R.105.5 RoPInterim conferenceEPO Board of Appeal decisionPharmaceutical patentGenerics
Dokumente
- 17DF80EA6AFBAEAF68A5A2DD0A31FF24_en.pdf2025-07-17EN